Carla L. Alves
Odense, 5230, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.
Journal: Science translational medicine
Published: December 17, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 15, 2025
Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.
Journal: Journal of personalized medicine
Published: April 10, 2025
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer.
Journal: Frontiers in oncology
Published: September 16, 2024
Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: A preclinical study of the theranostic pair [55Co]Co- and [177Lu]Lu-DOTA-RM26.
Journal: Nuclear medicine and biology
Published: June 11, 2024
Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
Journal: International journal of cancer
Published: January 22, 2024
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
Journal: International journal of molecular sciences
Published: January 31, 2023
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Journal: Cancer communications (London, England)
Published: December 05, 2022
Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer.
Journal: International journal of molecular sciences
Published: August 16, 2022
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
Journal: NPJ precision oncology
Published: December 17, 2021
Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies.
Journal: Cancers
Published: September 22, 2021
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Journal: Nature communications
Published: September 17, 2021
Last Updated: 09/26/2026